Kodiak Sciences to Report DAYBREAK Phase 3 Topline Data for Zenkuda and KSI-501 in Wet AMD
核心洞察
Kodiak Sciences will report topline results from the DAYBREAK Phase 3 study on September 28, 2026, evaluating Zenkuda and KSI-501 in wet age-related macular degeneration (搜索).
DAYBREAK runs two investigational arms in parallel within a single registrational trial, testing non-inferiority against aflibercept on visual acuity change from baseline.
Zenkuda already has a BLA-ready profile in diabetic retinopathy (搜索) and retinal vein occlusion (搜索), while KSI-501, a bispecific targeting VEGF (搜索) and IL-6, has no approved indication.
Kodiak Sciences will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer (搜索)) in patients with wet age-related macular degeneration (搜索), on Monday, September 28, 2026. The company announced the readout on September 25, 2026, and will host a webcast at 8:30 AM Eastern Time that day, with an archived replay available for a limited time.
The readout is unusual in design. DAYBREAK runs two molecularly distinct investigational arms in parallel inside a single registrational trial, so one dataset will speak to two separate development bets at once. The regulatory bar is non-inferiority to aflibercept, and the primary endpoint to watch is visual acuity change from baseline relative to aflibercept. Differentiation on durability or dosing interval is what would matter commercially beyond that threshold.
Two molecules, two different inflection points
Zenkuda carries a BLA-ready profile in diabetic retinopathy (搜索), retinal vein occlusion (搜索) and wet AMD, built on Phase 3 data already in hand, including positive results from the GLOW2 study in diabetic retinopathy. Wet AMD remains the gap the DAYBREAK readout addresses.
KSI-501 is earlier in its clinical story and has no approved indication. It is a bispecific agent targeting both the VEGF (搜索) and IL-6 pathways, and is being evaluated in wet AMD and diabetic macular edema (搜索). For KSI-501, DAYBREAK functions as a proof-of-concept test of its mechanism in a new disease context.
Kodiak describes itself as a precommercial, retina-focused biotechnology company developing next-generation retinal medicines intended to prevent and treat the leading causes of blindness globally. Zenkuda and KSI-501 together target the $15 billion slice of the anti-VEGF (搜索) market tied to retinal vascular diseases.
Competitive field in retinal vascular disease
The broader anti-VEGF (搜索) market was valued at roughly $26 billion in 2024, according to the competitive context around the readout. The field is not open: the FDA approved LYTENAVA (bevacizumab-vikg (搜索)) for wet AMD on July 24, 2026, adding another entrant alongside established agents.
Beyond DAYBREAK
Kodiak's pipeline extends past the September readout. KSI-101, a bispecific protein, is being explored in two BLA-facing Phase 3 studies in macular edema secondary to inflammation (搜索) (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026, and for Pivotal Analysis 2 (PEAK+PINNACLE) in the second quarter of 2027.
The September 28 webcast is the first of several major data windows the company expects to open before mid-2027.